Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain

• Status: Terminated
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Neuropathic pain is due to a lesion or disease affecting the nervous system. Antidepressants (ADs) are recommended as the first line treatment. In a murine model, the investigators evidenced that antidepressants antiallodynic action is mediated through β2-adrenergic receptor stimulation and that β-mimetics display the same effect. These data support the idea that β-mimetics could offer a therapeutic alternative to ADs for neuropathic pain treatment. This study will aim at assessing the effects of terbutaline on neuropathic pain symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Strasbourg, France
• Treatments: Analgesics; Terbutaline

Criteria

Inclusion Criteria:

• adults from 18 to 75 years old

• neuropathic painful condition following a thoracotomy or thoracoscopy for at least 3 months

Exclusion criteria:

• cardiovascular risk

• unstable diabetes mellitus

• allergy for terbutaline

• hypokaliemia without treatment

• untreated hypothyroidism

• HIV- or chemotherapy-induced neuropathy

• cancer being treated by chemo- or radio-therapy

• concomitant treatment with β-blockers, tricyclic ADs or morphine

• concomitant pain more severe than neuropathic pain- pregnant women